中国社区医师
中國社區醫師
중국사구의사
Chinese Community Doctors
2015年
32期
29-30
,共2页
慢性乙型肝炎%干扰素α-2b%替比夫定%临床疗效
慢性乙型肝炎%榦擾素α-2b%替比伕定%臨床療效
만성을형간염%간우소α-2b%체비부정%림상료효
Chronic hepatitis B%Interferon α-2b%Telbivudine%Clinical curative effect
目的：观察干扰素α-2b序贯替比夫定治疗HBeAg阳性慢性乙型肝炎的临床疗效。方法：将86例患者分为序贯组40例和对照组46例。序贯组为干扰素治疗6个月疗效欠佳的患者，停干扰素开始替比夫定继续治疗。对照组为替比夫定初治的患者。比较治疗后48、72、96周时疗效。结果：序贯组ALT复常率、HBeAg阴转率、HBV DNA阴转率在治疗48、72、96周时，分别为40.74%、88.88%、81.48%和48.14%、92.59%、85.18%；而对照组则分别为36.00%、72%、80.00%和44.00%、72.00%、84.00%；两组疗效经统计学分析，ALT复常率差异无统计学意义，HBeAg转阴率差异有统计学意义(P＜0.05)。结论：干扰素α-2b 序贯替比夫定治疗 HBeAg 阳性慢性乙型肝炎患者，在48、72、96周时HBeAg阴转率、HBVDNA阴转率均优于对照组。
目的：觀察榦擾素α-2b序貫替比伕定治療HBeAg暘性慢性乙型肝炎的臨床療效。方法：將86例患者分為序貫組40例和對照組46例。序貫組為榦擾素治療6箇月療效欠佳的患者，停榦擾素開始替比伕定繼續治療。對照組為替比伕定初治的患者。比較治療後48、72、96週時療效。結果：序貫組ALT複常率、HBeAg陰轉率、HBV DNA陰轉率在治療48、72、96週時，分彆為40.74%、88.88%、81.48%和48.14%、92.59%、85.18%；而對照組則分彆為36.00%、72%、80.00%和44.00%、72.00%、84.00%；兩組療效經統計學分析，ALT複常率差異無統計學意義，HBeAg轉陰率差異有統計學意義(P＜0.05)。結論：榦擾素α-2b 序貫替比伕定治療 HBeAg 暘性慢性乙型肝炎患者，在48、72、96週時HBeAg陰轉率、HBVDNA陰轉率均優于對照組。
목적：관찰간우소α-2b서관체비부정치료HBeAg양성만성을형간염적림상료효。방법：장86례환자분위서관조40례화대조조46례。서관조위간우소치료6개월료효흠가적환자，정간우소개시체비부정계속치료。대조조위체비부정초치적환자。비교치료후48、72、96주시료효。결과：서관조ALT복상솔、HBeAg음전솔、HBV DNA음전솔재치료48、72、96주시，분별위40.74%、88.88%、81.48%화48.14%、92.59%、85.18%；이대조조칙분별위36.00%、72%、80.00%화44.00%、72.00%、84.00%；량조료효경통계학분석，ALT복상솔차이무통계학의의，HBeAg전음솔차이유통계학의의(P＜0.05)。결론：간우소α-2b 서관체비부정치료 HBeAg 양성만성을형간염환자，재48、72、96주시HBeAg음전솔、HBVDNA음전솔균우우대조조。
Objective:To observe the clinical curative effect of interferon α-2b sequential telbivudine in the treatment of HBeAg positive chronic hepatitis B.Methods:86 patients were divided into the sequential group with 40 cases and the control group with 46 cases.The sequential group was the patients who were given interferon treatment for 6 months with poor curative effect,and it stopped interferon,began to the telbivudine continuous treatment.The control group was the patients with telbivudine initial.The curative effects were compared in 48、 72、 96 weeks after treatment.Results:In 48、 72、 96 weeks after treatment,the ALT normalizing rates,HBeAg negative conversion rates,HBV DNAnegative conversion rates of the sequential group were respectively 40.74%、88.88%、81.48% and 48.14%、92.59%、85.18%.Those of the control group were respectively 36.00%、72%、80.00% and 44.00%、72.00%、84.00%.The curative effects of two groups were statistically analyzed,the ALT normalizing rates were not statistically significant,the difference between the HBeAg negative conversion rates was statistically significant(P<0.05). Conclusion:In the interferon α-2b sequential telbivudine in the treatment of patients with HBeAg positive chronic hepatitis B, the HBeAg negative conversion rates,HBV DNAnegative conversion rates in 48、72、96 weeks were better than those of the control group.
